

## WHO Prequalification Programme WHO PUBLIC ASSESSMENT REPORT (WHOPAR)

### TERIZIDON<sup>1</sup>

#### Terizidone 250 mg Capsules

TERIZIDON was submitted in 2017 by RIEMSER Pharma GmbH to be considered for prequalification and subsequently accepted for the WHO list of prequalified products for the treatment of tuberculosis on 14 March 2018.

Information on the site(s) involved in the manufacture of the product and the API is available at the products listing information <https://extranet.who.int/pqweb/medicine/4133>

The marketing authorization holder transferred to Esteve Pharmaceuticals GmbH in 2023.

The “Procedure for prequalification of pharmaceutical products<sup>2</sup>” defines specific evaluation mechanisms for products approved by regulatory authorities, which apply similar stringent standards for quality, safety and efficacy as those required by WHO.

The prequalification of this product by the WHO Prequalification Team: Medicines (PQTm), is based on the approval by the German “Federal Institute for Drugs and Medical Devices” ([https://www.bfarm.de/EN/Home/home\\_node.html](https://www.bfarm.de/EN/Home/home_node.html)) in line with the “Guidelines on submission of documentation for prequalification of finished pharmaceutical products approved by stringent regulatory authorities”<sup>3</sup>.

Hence, no assessment of the data underlying this approval has been undertaken within the WHO Prequalification Programme.

However, according to the SRA guideline WHO may request additional data when considered necessary for the safe use of the product in regions relevant for prequalified products and such information may be included in the WHOPAR as a separate piece of information. In order to safeguard product quality throughout its entire intended shelf-life in hot and very humid areas, stability studies under the conditions defined for Climatic Zones IVb have been requested from the Applicant<sup>4</sup>.

Based on the submitted stability data WHO PQTm considers the following storage condition appropriate for the product when distributed in regions with zone III, IVa and IVb climatic conditions, based on available stability information:

- Do not store above 25°C. Avoid excursions above 30°C.
- The shelf-life at this storage condition is 36 months.

---

<sup>1</sup> Trade names are not prequalified by WHO. This is the National Medicines Regulatory Authority’s responsibility. Throughout this WHOPAR the proprietary name is given as an example only.

<sup>2</sup> [https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/prequalification/trs961-annex10-who-procedure-prequalification.pdf?sfvrsn=85029f47\\_2](https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/prequalification/trs961-annex10-who-procedure-prequalification.pdf?sfvrsn=85029f47_2)

<sup>3</sup> [https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/prequalification/trs986-annex5.pdf?sfvrsn=8aae767d\\_2](https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/prequalification/trs986-annex5.pdf?sfvrsn=8aae767d_2)

<sup>4</sup> [https://extranet.who.int/pqweb/sites/default/files/documents/48 Stability data SRA FPPs\\_March2016\\_newtempl.pdf](https://extranet.who.int/pqweb/sites/default/files/documents/48%20Stability%20data%20SRA%20FPPs_March2016_newtempl.pdf)

This WHOPAR refers to the information available at the approving stringent regulatory authority's website resulting from the assessment of the quality, efficacy and safety as well as steps taken after approval.

([Arzneimittel-Informationssystem \(dimdi.de\)](https://www.dimdi.de) Registration nr 82515.00.00)

For details on the uses of this product, for relevant efficacy and safety information see the summary of product characteristics and the patient information leaflet

The English language version of the patient information leaflet, the summary of product characteristics and the labelling, as certified to be "BfArM" approved texts, are included in this WHOPAR.

This WHOPAR for TERIZIDON is comprised of parts 2, 3, 4, 5 and 7.

TERIZIDON contains terizidone. Its WHO recommended use is for the treatment of tuberculosis.

The efficacy and safety profile of terizidone is well established based on the extensive clinical experience in the treatment of tuberculosis.

#### Summary of Prequalification Status for TERIZIDON

Initial acceptance	Date	Outcome
Status on PQ list	14 March 2018	listed
Quality	March 2018	MR
PQ: prequalification MR: meets requirements		

The table represents the status of relevant completed activities only.